Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of PRCT is 33 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell